Results 61 to 70 of about 3,791 (213)

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

The role of [68 Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST)

EJNMMI Research, 2021
Background [68 Ga]Ga-DOTATATE PET/CT is now recognised as the most sensitive functional imaging modality for the diagnosis of well-differentiated neuroendocrine tumours (NET) and can inform treatment with peptide receptor radionuclide therapy with [177Lu]
Luigi Aloj, Olivier Giger, Iosif A. Mendichovszky, Ben G. Challis, Meytar Ronel, Ines Harper, Heok Cheow, Rogier ten Hoopen, Deborah Pitfield, Ferdia A. Gallagher, Bala Attili, Mary McLean, Robin L. Jones, Palma Dileo, Venkata Ramesh Bulusu, Eamonn R. Maher, Ruth T. Casey   +16 more
doaj   +1 more source

Clinical Utility of 68Ga‐DOTATOC Positron Emission Tomography/Computed Tomography in Evaluating Metastatic Lesions of Clear Cell Renal Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine, Toru Sakatani, Sho Koyasu, Takashi Ogata, Yuki Teramoto, Akio Sakamoto, Takashi Mizowaki, Yuji Nakamoto, Takashi Kobayashi, Takayuki Goto   +9 more
wiley   +1 more source

Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu‐DOTA‐TATE: Ad Hoc Analysis of the Phase III NETTER‐1 Trial

Cancer Medicine
Background In many solid tumors, early tumor shrinkage predicts the durability of treatment response. It is unclear whether this is the case for neuroendocrine tumors treated with peptide receptor radionuclide therapy (PRRT).
Marianne Pavel, Martyn E. Caplin, Philippe Ruszniewski, Marianna Hertelendi, Eric P. Krenning, Jonathan R. Strosberg, the NETTER‐1 Study Group   +6 more
doaj   +1 more source

Filters Effect on Image Quality of 177Lu-DOTATATE SPECT Images for Neuro-Endocrine Tumors Scanning

Frontiers in Biomedical Technologies
Purpose: The quality of the image in SPECT scans depends on the imaging parameters which are determined experimentally in the field of nuclear medicine.
Hussein Dakhil, Mohammad Reza Deevband, Mahasti Amoui, Ahmad Mostaar, Mahdi Ghorbani, Mohsen Khosroabadi, Mohammad Ali Ghodsirad   +6 more
doaj   +1 more source

Design and validation of a deep learning GAN for predicting 177Lu dose voxel kernels using GATE/GEANT4 Monte Carlo and IDAC‐Dose 2.1 in phantom dosimetry

Journal of Applied Clinical Medical Physics, Volume 27, Issue 6, June 2026.
Abstract Background The rapid evolution of deep learning (DL), particularly the emergence of generative adversarial networks (GANs) has demonstrated strong potential for generating high‐resolution, voxel‐level dosimetric data. However, GAN‐based approaches have not yet been broadly applied to the generation of tissue‐specific dose voxel kernels (DVKs ...
Otieno Erick Kapis, Muchai Ian Kaniu, Iaccarino Giuseppe, Hudson Kalambuka Angeyo   +3 more
wiley   +1 more source

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)

European Journal of Nuclear Medicine and Molecular Imaging, 2023
Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response
R. Alipour, Peter Jackson, M. Bressel, A. Hogg, J. Callahan, R. Hicks, G. Kong   +6 more
semanticscholar   +1 more source

Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment

Journal of Neuroendocrinology, Volume 38, Issue 6, June 2026.
Abstract Neuroendocrine tumours (NETs) are well‐differentiated epithelial neuroendocrine neoplasms that frequently develop in the small intestine, pancreas, and lungs. NETs originate from neuroendocrine cells specialized in hormone secretion implicated in a number of physiological processes.
Victoria Jacquot, Benjamin Chevalier, Thomas Walter, Benjamin Gibert, Maria Ouzounova   +4 more
wiley   +1 more source

Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

EJNMMI Physics, 2019
Background 177Lu-DOTATATE peptide receptor radionuclide therapy is administered to patients on an inpatient and outpatient basis for the treatment of well-differentiated, metastatic neuroendocrine tumours. Following administration, these patients present
D. Levart, E. Kalogianni, B. Corcoran, N. Mulholland, G. Vivian   +4 more
doaj   +1 more source

A Biochemically “Silent” Aortocaval Paraganglioma in a 19‐Year‐Old Female Causing Intraoperative Hypertensive Crisis: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Paragangliomas may appear biochemically silent, yet still behave as functional tumors with severe intraoperative consequences. Normal preoperative catecholamine screening does not exclude the risk of hypertensive crisis during surgery.
Abdul Basit, Tooba Yaqoob, Eyman Farrukh, Abdullah Iftikhar, Muhammad Usman Ali Khan, Majeed Haq   +5 more
wiley   +1 more source